by Nancy Lapido
(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to confirm the findings and that has not yet been substantiated by peer review.
COVID-19 worsens asthma in children
Doctors have warned that asthma can worsen in children after infection with the coronavirus.
They studied nearly 62,000 US children with asthma who underwent a PCR test for the virus in the first year of the pandemic, including more than 7,700 who tested positive. Researchers report in the Journal of Allergy and Clinical Immunology: In Practice that infected children had higher rates of asthma attacks, hospitalizations, emergency inhaler use and steroid treatment during the six months following their illness, compared with children who did not have any symptoms. who had tested negative and their own prior history. https://www.jaci-inpractice.org/article/S2213-2198(22)00360-9/fulltext. Christine Chow, of Children’s Health of Orange County in California, said, “Children who tested negative for the virus had improved asthma control for the next six months, meaning fewer emergency department visits and asthma.” for hospitalization, and less asthma treatment.”
He said the results of earlier studies showing improvements in asthma control in the early stages of the pandemic were due to public health measures such as staying home and wearing masks, which reduced exposure to asthma triggers. Despite the overall belief that children with asthma did well during the first year of the pandemic, Chou said, the new study shows “the long-lasting harm of COVID on children’s asthma control.”
After Transition Booster Adds A Little Extra Benefit Vs Omicron
In people who were previously infected with the coronavirus, a third dose of mRNA vaccine from Pfizer/BioNtech or Moderna may not boost their protection against the Omicron version of the virus, according to new data.
Researchers studied nearly 130,000 people tested for COVID in Connecticut from November 2021 to January 2022, including 10,676 people with Omicron infection. According to a report posted on medRxiv https://www.medrxiv.org/content/10.1101/2022.04.19.22274056v3 prior to peer review, roughly 6% to 8% were infected with previous versions of the coronavirus. Two doses of the mRNA vaccine helped protect against Omicron in people with prior infection, said Margaret Lind of Yale University, but “we did not detect an additional benefit of receiving a third booster dose among this population.”
A separate study from Canada, also posted on medRxiv https://www.medrxiv.org/content/10.1101/2022.04.29.22274455v1 prior to peer review, similarly found that more than two vaccine doses were “of marginal incremental value.” May” protect already infected individuals against omicrons. The message, Lind said, “should be that (1) people should get two doses of the mRNA vaccine, regardless of whether or not they’ve had a prior infection, (2) people with no prior infection should get a booster dose and that ( 3) People with prior infection should consider a booster dose, especially if they are in a high risk group for life-threatening complications, but recognize that this does not provide significant additional protection against infection above two doses Can do.”
Click for Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.
(Reporting by Nancy Lapid; Editing by Bill Burcrot)